CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishChemotherapy and vaccination with tumor-loaded dendritic cells (DCs) show poor impact on overall survival (OS) in metastatic melanoma1,2. Ipilimumab (IPI) improves OS throughout the blockade of CTLA4-mediated inhibitory signals in T-cells and restores the efficiency of the antigenic cross-priming by mature (m) DCs3. However, variation of immune cells to evaluate the response to IPI does not reflect the T-cell activation and is a modest predictor of clinical response. Recent studies in human and experimental melanoma demonstrated that mDCs release endomysial microvescicles namely dexosomes (Dex) showing a functional anti-melanoma activity as well as an antigenic profile resembling that of circulating mDCs including CD40, CD80 and CD86 co-stimulatory molecules. This research is aimed to identify an early biomarker of T-cell activation for predicting the clinical response in IPI-treated melanoma patients.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. | |
| Autori: | ||
| Data di pubblicazione: | 2015 | |
| Rivista: | ||
| Abstract: | Chemotherapy and vaccination with tumor-loaded dendritic cells (DCs) show poor impact on overall survival (OS) in metastatic melanoma1,2. Ipilimumab (IPI) improves OS throughout the blockade of CTLA4-mediated inhibitory signals in T-cells and restores the efficiency of the antigenic cross-priming by mature (m) DCs3. However, variation of immune cells to evaluate the response to IPI does not reflect the T-cell activation and is a modest predictor of clinical response. Recent studies in human and experimental melanoma demonstrated that mDCs release endomysial microvescicles namely dexosomes (Dex) showing a functional anti-melanoma activity as well as an antigenic profile resembling that of circulating mDCs including CD40, CD80 and CD86 co-stimulatory molecules. This research is aimed to identify an early biomarker of T-cell activation for predicting the clinical response in IPI-treated melanoma patients. | |
| Handle: | http://hdl.handle.net/11586/139784 | |
| Appare nelle tipologie: | 1.5 Abstract in rivista |
File in questo prodotto:
Copyright © 2021